Chief Medical Officer · RECURSION PHARMACEUTICALS, INC. (RXRX)

Ramona Doyle

A named executive officer of RECURSION PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,207,406

Salary $167,933Stock awards $475,848

FY2021: $607,456

5th of 5 named executive officers at Recursion Pharmaceuticals by FY2022 total.

5 named officers on file for RECURSION PHARMACEUTICALS, FY2022

Ramona Doyle’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • RXRX’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how RECURSION PHARMACEUTICALS’s whole pay program stands against its peers

  • RECURSION PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RXRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Ramona Doyle’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ramona Doyle compensation by year

RECURSION PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as RECURSION PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$3,666$440,282$167,933
Bonus$0$0—
Stock awards$0$0$475,848
Option awards$1,134,331$0$563,625
Non-equity incentive$0$154,000—
Pension and deferred compensation$0$0—
All other$0$13,174$359,058
Total$1,137,997$607,456$1,207,406

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RECURSION PHARMACEUTICALS, INC. DEF 14A filed April 28, 2023, accession 0001601830-23-000013, and prior-year filings.

How this page was built: the RECURSION PHARMACEUTICALS, INC. filed document, accession 0001601830-23-000013. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$1.1M
$607K
$1.2M
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

RECURSION PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Christopher GibsonChief Executive Officer$6,303,703
Tina Marriott LarsonChief Operating Officer and President$2,750,640
Michael SecoraChief Financial Officer$2,044,318
Shafique ViraniChief Corporate Development Office$1,756,314
Ramona Doyle · this pageChief Medical Officer$1,207,406

The full RECURSION PHARMACEUTICALS compensation record

free company brief

This page is one person within RECURSION PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the RECURSION PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RECURSION PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ramona Doyle's compensation dossier · One-time report. No refunds.